AMS · American Shared Hospital Services - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $28.08M | $28.34M | $21.32M | $19.75M | $17.63M | $17.84M |
| Cost of Revenue | $23.02M | $19.16M | $11.98M | $11.36M | $13.37M | - |
| Gross Profit | $5.06M | $9.19M | $9.34M | $8.38M | $6.73M | $4.47M |
| R&D | - | - | - | - | - | - |
| SG&A | $7.08M | $7.41M | $7.02M | $5.14M | $4.53M | $4.61M |
| Total Operating Expenses | - | - | - | - | - | $13.37M |
| D&A | $5.71M | $6.17M | $4.78M | $4.78M | $4.97M | $6.97M |
| Operating Income | ($3.59M) | ($2.81M) | $270.0K | $2.43M | $1.35M | ($9.46M) |
| Interest Expense | $1.57M | $1.50M | $1.11M | $806.0K | $739.0K | $1.06M |
| Income Tax | ($493.0K) | ($295.0K) | $431.0K | $963.0K | $269.0K | ($1.74M) |
| Net Income | ($1.55M) | $2.19M | $610.0K | $1.33M | $194.0K | ($7.06M) |
| EPS - Basic | ($0.23) | $0.34 | $0.10 | $0.21 | $0.03 | ($1.14) |
| EPS - Diluted | ($0.23) | $0.33 | $0.10 | $0.21 | $0.03 | ($1.14) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.46M | $11.03M | $13.69M | $12.34M | $8.14M | $3.96M |
| Accounts Receivable | $10.52M | $11.61M | $4.34M | $3.80M | $4.21M | $4.30M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $607.0K | $1.56M | $315.0K | $230.0K | $746.0K | $683.0K |
| Current Assets | $17.72M | $26.26M | $20.46M | $18.72M | $15.09M | $10.85M |
| Total Assets | $55.48M | $60.20M | $48.16M | $43.96M | $45.43M | $43.65M |
| Current Liabilities | $23.44M | $10.40M | $10.78M | $5.17M | $5.89M | $12.38M |
| Long-term Debt | $0 | $17.34M | $11.04M | $12.21M | $14.32M | $3.44M |
| Total Liabilities | $27.79M | $30.17M | $21.88M | $18.33M | - | - |
| Stockholders' Equity | $24.03M | $25.18M | $22.62M | $21.63M | $19.89M | $19.27M |
| Retained Earnings | $4.26M | $5.82M | $3.63M | $3.02M | $1.69M | $1.50M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $3.10M | $167.0K | $5.72M | $7.24M | $6.27M | $9.74M |
| Investing Cash Flow | ($7.63M) | ($7.11M) | ($6.27M) | ($388.0K) | ($1.67M) | ($2.39M) |
| Financing Cash Flow | ($3.03M) | $4.41M | $1.91M | ($2.66M) | ($655.0K) | ($4.81M) |
| CapEx | $7.63M | $7.94M | $6.27M | $388.0K | $1.67M | $455.0K |
| Free Cash Flow | ($4.54M) | ($7.77M) | ($555.0K) | $6.85M | $4.59M | $9.29M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 18.0% | 32.4% | 43.8% | 42.4% | 38.2% | 25.0% |
| Operating margin | -12.8% | -9.9% | 1.3% | 12.3% | 7.7% | -53.1% |
| EBITDA margin | 7.6% | 11.9% | 23.7% | 36.5% | 35.9% | -14.0% |
| Net margin | -5.5% | 7.7% | 2.9% | 6.7% | 1.1% | -39.6% |
| Free cash flow margin | -16.2% | -27.4% | -2.6% | 34.7% | 26.1% | 52.1% |
| FCF / Net income | 2.92 | -3.55 | -0.91 | 5.16 | 23.68 | -1.32 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 25.2% | 26.1% | 32.9% | 26.1% | 25.7% | 25.8% |
| Effective tax rate | - | -15.6% | 41.4% | 42.0% | 58.1% | - |
| Return on assets | -2.8% | 3.6% | 1.3% | 3.0% | 0.4% | -16.2% |
| Return on equity | -6.5% | 8.7% | 2.7% | 6.1% | 1.0% | -36.6% |
| Return on invested capital | -11.8% | -6.6% | 0.5% | 4.2% | 2.0% | -32.9% |
| Liquidity | ||||||
| Current ratio | 0.76 | 2.52 | 1.90 | 3.62 | 2.56 | 0.88 |
| Quick ratio | 0.76 | 2.52 | 1.90 | 3.62 | 2.56 | 0.88 |
| Cash ratio | 0.15 | 1.06 | 1.27 | 2.38 | 1.38 | 0.32 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.69 | 0.49 | 0.56 | 0.72 | 0.18 |
| Debt / Assets | 0.00 | 0.29 | 0.23 | 0.28 | 0.32 | 0.08 |
| Debt / EBITDA | 0.00 | 5.15 | 2.19 | 1.69 | 2.27 | - |
| Interest coverage | -2.3x | -1.9x | 0.2x | 3.0x | 1.8x | -9.0x |
| Equity multiplier | 2.31 | 2.39 | 2.13 | 2.03 | 2.28 | 2.26 |
| Liabilities / Assets | 0.50 | 0.50 | 0.45 | 0.42 | - | - |
| Efficiency | ||||||
| Asset turnover | 0.51 | 0.47 | 0.44 | 0.45 | 0.39 | 0.41 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 137d | 150d | 74d | 70d | 87d | 88d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | 10d | 30d | 10d | 7d | 20d | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -0.9% | 32.9% | 8.0% | 12.0% | -1.2% | -8.8% |
| Revenue CAGR (3y) | 12.5% | 17.1% | 6.1% | 0.3% | -1.9% | - |
| Revenue CAGR (5y) | 9.5% | 7.7% | 2.7% | - | - | - |
| Gross profit growth (YoY) | -44.9% | -1.7% | 11.5% | 24.6% | 50.6% | -35.5% |
| Operating income growth (YoY) | -27.9% | - | -88.9% | 79.9% | - | - |
| Net income growth (YoY) | - | 258.4% | -54.1% | 584.5% | - | - |
| EPS growth (YoY) | - | 230.0% | -52.4% | 600.0% | - | - |
| EPS CAGR (3y) | - | 122.4% | - | 24.1% | -43.9% | - |
| EPS CAGR (5y) | - | 24.6% | -10.1% | -8.6% | -29.3% | - |
| FCF growth (YoY) | 41.6% | -1300.2% | - | 49.1% | -50.6% | 31.6% |
| FCF CAGR (5y) | - | - | - | -2.0% | -7.5% | 7.0% |
| Book value growth (YoY) | -4.6% | 11.3% | 4.6% | 8.7% | 3.2% | -26.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$28.08M totalDirect Patient Services$15.53M · 55.3%
Medical Equipment Leasing$12.55M · 44.7%
Product / service
$28.08M totalPatient Income$15.53M · 55.3%
Rental Income From Medical Services$12.55M · 44.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.66
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing AMERICAN SHARED HOSPITAL SERVICES against the 5 most active filers in the same SIC group.